Introduction
Alzheimer's disease (AD) impairs cognition, memory, and language and causes dementia. In 1907, Aloïs Alzheimer described the extensive distribution of neuronal tangles and amyloid plaques in brain that, together with astrogliosis, neuronal dystrophy, neuronal loss, and vascular alterations, constitute the hallmarks of the disorder.
For over 20 years, the ''amyloid cascade hypothesis'' has provided the main theoretical construct for AD (Hardy and Selkoe, 2002) . It proposes amyloid plaques or their major constituents, the Ab-peptides, as the direct cause of the progressive neurodegeneration. The concept that a biochemical/biophysical process underlies the complex cognitive alterations has transformed AD research, replacing earlier descriptive studies with a molecular, mechanistic view. This has led to diagnostic and therapeutic trials for a disease believed before to be either incurable or an inevitable consequence of aging. The tremendous increase in knowledge on the molecular biology, pathophysiology, and diagnosis of AD is exciting and holds promise for future prevention and therapies but also starts to erode the assumptions of its main theoretical foundation.
To understand the disease, the well-studied biochemistry needs to be integrated into the complex cellular context of the brain. We examine here how a failing vascular system contributes to disease progression; how inhibitory and excitatory neurons, neuronal networks, microglia, astroglia, and, finally, oligodendrocytes all contribute to a complex cellular phase of the disease evolving over decades, and how initial benign reactions ultimately become chronic, resulting in an irreversible dyshomeostasis of the brain. Emerging approaches could provide us with a more holistic understanding of the spatial, temporal, and cellular aspects of the disease process. We start with a brief critique of the amyloid cascade hypothesis itself.
The Amyloid Hypothesis
The amyloid hypothesis for AD is a neuron-centric, linear, and quantitative model postulating direct cause and consequences in a cascade initiated by Ab deposition and leading progressively to Tau pathology, synaptic dysfunction, inflammation, neuronal loss, and, ultimately, dementia.
The linearity of the cascade remains very controversial. For instance, exploration of the direct link between Ab and neurotoxicity has resulted in a rather confusing literature with at least ten different molecular mechanisms and receptors (see Figure 1 ) . It is debatable whether they all equally contribute to the disease process in humans, as many of the supporting studies used non-physiologically high concentrations of Ab or transgenic mice significantly overexpressing APP (see Nilsson et al., 2014) . However, an alternative explanation for the richness of these findings is that different mechanisms or even the same mechanism exert multiple effects at different stages of disease progression. For instance, the interaction of Ab with the receptor for advanced glycation end products (RAGE) causes oxidative stress in neurons but enhances inflammatory responses in microglia and is involved in endothelial cells in ''reversed'' transport of Ab across the blood-brain barrier (BBB) (Deane et al., 2012) . Thus, the neuron-centric view has to be expanded to one that considers the contribution of different cell types, their interactions with each other, and the gradual evolution of the disease.
Preclinical or prodromal AD stages have been defined by clinicians to underscore the concept that AD starts insidiously many decades before full dementia becomes apparent (Carrillo et al., 2013; Dubois et al., 2014) . The amyloid cascade hypothesis provides no explanation for the silent incubation period of AD. Even in familial AD (FAD) , where the role of Ab is established because of causative mutations in APP and Presenilin, the amyloid hypothesis is found wanting. Why, for instance, does abnormal Ab production, already present from conception, manifest its toxicity only in midlife? Clearly the complex compensation mechanisms in the brain that maintain almost normal cognitive performance for decades should be accommodated into any theoretical construct of the disease. In our view, AD only starts when a pathological cellular reaction is initiated.
The quantitative aspects of the hypothesis (the concept that more amyloid plaques, or, in more recent versions, more Ab 42 , is causing disease) imply that quantitative lowering of Ab-plaques or Ab-oligomers should be sufficient to halt progression of AD (critically discussed in Karran et al., 2011) . The discrepancy between amyloid load and disease symptoms in sporadic AD (SAD) has, however, been pointed out in the past: ''it seems as if the Ab plaques appear at the wrong time and in the wrong places with respect to the clinical dementia'' (Mesulam, 1999) . Less appreciated is the fact that the quantitative concept is equally not tenable for FAD. Most Presenilin (PSEN1) mutations do not increase Ab generation. PSEN1 is part of the g-secretase complex, and mutations affect mainly the ''trimming'' function of these proteases whereby the C-terminal region of long Ab is progressively cleaved. The mutations might destabilize the three-dimensional structure of the g-secretases, which might explain the premature release of longer (insufficiently ''trimmed'') hydrophobic Ab 42, Ab 43 , and, hypothetically, Ab >43 , peptides (Chá vez-Gutié rrez et al., 2012; Szaruga et al., 2015; Saito et al., 2011) . In this view, even lowering of total Ab could still be pathogenic if the Ab produced is longer than Ab 40 . Such long Ab, even in low amounts, could provide seeds for further nucleation and amyloidosis. Thus, in contrast to what is assumed in the amyloid hypothesis, the pathological effects of the PSEN1 mutations on Ab production are qualitative and not quantitative (Kuperstein et al., 2010; Szaruga et al., 2015) . All membrane receptors implied in Ab pathogenic mechanisms are indicated. Some receptors are only indirectly affected by Ab, inferred by physiological alterations of cells exposed to Ab. The second series are receptors shown to directly bind Ab (see Benilova et al., 2012) .
The Biochemical Phase in AD Causes Proteostatic Stress and Homeostatic Cellular Responses
The ''biochemical phase'' of AD is characterized by abnormal aggregation of Ab and potentially abnormal processing of APP; formation of Tau conformers followed by hyper phosphorylation; the seeding and propagation in a prionoid fashion of these abnormally folded proteins (Walker and Jucker, 2015) ; the generation of oligomeric amyloids (Abo-and Tau-oligomers); and the generation of amyloid plaques and neuronal tangles. The different conformations of Ab and Tau exert ''proteopathic'' or ''aggregrate'' stress on different cells of the brain, i.e., they interact with proteins and membranes and interfere with signaling and other functions. They also bind APP and Tau, which disturbs the normal activities of these proteins in neurotransmission (Palop and Mucke, 2010) . The temporal sequence of these events is undefined. Age-related deficiencies of the proteostatic network could cause accumulation of aggregating proteins; conversely, protein aggregates might disturb the complex cellular molecular network that sustains protein folding (Labbadia and Morimoto, 2015) . The lysosomal/endolysosomal system and, in particular, autophagy is a key regulator of this proteopathic stage (Nixon, 2013) . In AD brains, a striking increase in classic autophagosomes, featuring a double membrane that encapsulates heterogenous intracellular components, is seen in an early stage of the disorder (Nixon, 2013) . Deletion of key macroautophagy components such as ATG5 or ATG7 in neurons in mice causes motor deficits, ubiquitinated neuronal inclusions, and neurodegeneration (Komatsu et al., 2006) . In NiemannPick's disease type C, loss of function of the NPC1 or NPC2 genes leads to late endosomal/lysosomal accumulation of lipids and defective autophagocytosis (Elrick et al., 2012) . Affected neurons display tau inclusions that are indistinguishable from those in AD. Thus, abnormalities in autophagy are linked to tau pathology. The genetic support for a role of autophagy in AD compared to Parkinson disease, for example, remains surprisingly limited, however (Lambert et al., 2013) None of the initial effects of proteopathy should be considered overwhelming or irreversible, as brain cells can apparently survive this stress for many years. The elicited responses are physiological and can be cell or non-cell autonomous. They can be biochemical, maintaining homeostasis in the proteostatic network (Labbadia and Morimoto, 2015) , or functional, involving various synaptic plasticity mechanisms in which astroglia may play crucial roles. Inflammatory responses contribute initially to sustaining homeostasis. It is only when these compensating mechanisms turn into chronic, irreversible, and pathological processes that disease progresses inexorably. The transition of an early reversible to a chronic, irreversible, autonomous cellular response, likely no longer dependent on the initial Ab and Tau aggregate stressors, represents a critical phase in the disease process.
The separate locations of Tau and amyloid pathology and their natural progression in the brain (Braak and Braak, 1995; Thal et al., 2002) suggest that the two biochemical pathologies progress relatively independently from each other (Mesulam, 1999; Small and Duff, 2008) . Tangles are universally found in all aged people and are already present early in life (Braak and Del Tredici, 2011 ). This primary age-related tauopathy or PART (Crary et al., 2014) is mild. The effects of age-associated Ab accumulation are initially also mild-they are found in many aged people without causing clinical symptoms of brain dysfunction. Ab stress might enhance the progression of Tau pathology (Khan et al., 2014) , but described molecular links are multiple and indirect. Alternatively, Ab-stress and PART could be considered independent stressors that each cause a slowly evolving, relatively benign, age-related neurodegenerative process with no or only mild symptomatology. Only when they come together and reciprocally augment their deleterious effects is a more aggressive disease manifested with multiple cellular effects. Even in pure FAD, this scenario is conceivable: the abnormal Ab generated by the mutations becomes only part of a disease process when the ''natural'' process of progressive accumulation of neurofibrillar tangles has reached a threshold and both pathologies start to interact. The rather stereotypical evolution of the disease is compatible with this view (Karran et al., 2011) .
In the current Review, we try to go beyond the discussionwhich is nevertheless important-of the biochemistry and toxicity of Ab and Tau (De Strooper, 2010) . We see AD as a complex process consisting of different interacting phases encompassing feedback and feedforward mechanisms between cells, which, after many years, lead to dementia. Most importantly, in this view, Ab and Tau accumulations in SAD are considered risk factors-i.e., even if their accumulation is a sign of increased proteopathic stress, additional cellular factors are determinative in the evolution toward dementia. Instead of Ab and Tau, the real causes of sporadic disease are upstream of these proteopathies and are likely manifold, with aging being the major driver. Nevertheless, the proteopathic stress of the biochemical phase results in the cellular phase of AD. The clinical phase of the disease is initiated when the cellular reaction can no longer maintain homeostasis (Figure 2 ).
Defective Clearance Mechanisms Are Part of the Initial Cellular Phase Defective clearance of Ab (and Tau), considered to underlie the majority of sporadic AD cases, illustrates the complexity of the cellular response. Many proteases can break down Ab peptides in the biochemical phase (Figure 2 ) (De Strooper, 2010) , but, as shown by injecting labeled Ab or Tau in the brain parenchyma and following its elimination (Iliff et al., 2014) , it is now clear that a large part of normal Ab turnover depends on bulk flow via the perivascular circulation and the glymphatic system in the brain (Tarasoff-Conway et al., 2015) . Genetic risk associated with APOE4, PICALM, and APOJ (or CLU) is thought to affect Ab clearance (Verghese et al., 2013; Zhao et al., 2015) .
The cellular component of the clearance system is complex. The BBB consists of tightly connected endothelial cells and astroglia end-feet. Pericytes and smooth muscle cells provide contractile elements. The glia barrier is relatively open because of gap junctions allowing passage of Ab and Tau. The endothelial barrier is, however, not permeable, and therefore, specialized transport proteins (receptors of the LDL receptor family, e.g., LRP1&2, RAGE, ABC transporter ABCB1 or P-glycoprotein, ABCA1, and Ab free or bound to proteins such as a2-macroglobulin, APOJ, or APOE particles) are responsible for Ab (and Tau) egress to the circulation. For instance, heterozygote Picalm +/À mice show decreased LRP1-mediated clearance of Ab via the BBB. Although neurons with downregulated Picalm produce less Ab, accelerated amyloidosis and worsening in behavioral parameters is seen in these mice: this could be rescued via adenoviral expression of PICALM in the endothelium (Zhao et al., 2015) . PICALM proteolysis has also been associated with Tau-tangle formation and disturbed endocytosis in SAD (Ando et al., 2013) . The multifactorial effects of genes involved in AD are a recurrent theme in this Review and illustrate the importance of placing the biochemical process into the context of the cellular phase.
In contrast to Ab, much less is known regarding Tau clearance. Previously, Tau pathology was seen as a cell-autonomous phenomenon, and studies of Tau clearance were predominantly focused on intracellular processes such as autophagy. However, Tau pathology can progress through the brain in a prion-like The transition of biochemical to cellular and cellular to clinical phases are indicated. The cellular phase is complex and evolves gradually over two decades from reversible physiological reactions upon proteopathic stress to irreversible immune and electrophysiological compensation mechanisms that disturb the normal homeostasis of the brain. The effects are cell and non-cell autonomous and occur in the context of neurovascular or glioneuronal units (see main text). Processes are derived from GWAS studies (clearance dysfunction, lipid metabolism, immune response, protein trafficking) and are indicated in different colors. Genes are in italics when genetic evidence links them to AD. Other genes (LRP1, RAGE and others) are functionally implicated in the disease process. Each gene is associated to a color code indicating the pathways in which they operate. The picture is a late self-portrait from the German painter William Utermohlen, who suffered from AD. Image courtesy of Chris Boïcos Fine Arts, Paris.
fashion (Walker and Jucker, 2015) , and Tau is secreted after increased electrical activity (Yamada et al., 2014) . Some secreted Tau is cleared by the glymphatic flow (Iliff et al., 2014) ; thus, it is reasonable to predict that Tau gets cleared from the brain via similar cell-regulated bulk flow pathways as Ab. However, the role of the vasculature in AD goes far beyond clearance.
The Neurovascular Unit and the Vascular Hypothesis for AD The term ''neurovascular unit'' is used to describe the close anatomic and functional interrelationship between the cellular components of the brain. The vascular hypothesis proposes that initial vascular damage precipitates AD. Hypoperfusion and hypoxia are one aspect of the problem, but the associated breakdown of the BBB also results in accumulation of neurotoxic serum proteins in brain, inflammation, vascular, and synaptic dysfunction that lead secondarily to defects in Ab and Tau metabolism and clearance, which in turn cause vascular problems such as cerebral amyloid angiopathy (CAA) (Zlokovic, 2011) . CAA is caused by widespread deposition of Ab in the vasculature, resulting in fibrinoid necrosis, microaneurysms, and bleedings. Co-existence of AD and vascular pathology increases the risk for dementia considerably (Attems and Jellinger, 2014) .
Many functional studies support the central postulate of the vascular hypothesis-i.e., the primacy of vascular lesions in driving the AD phenotype (Zlokovic, 2011) . Mice that express the major genetic risk factor for AD, human APOE4 (on a mouse ApoE À/À background), show a curious degenerative response of endothelial cells and pericytes mediated by cyclophylin A and NFkb that leads to damage of the BBB (Bell et al., 2012) , which is also seen in human APOE4 carriers. Other genetic manipulations of receptors, transporters, and cells support the idea that early alterations in the BBB could play a major role in the initiation of AD. For example, AD patients typically display diminished glucose uptake in the brain as measured by 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) (Protas et al., 2013) . Interestingly, heterozygous deficiency of GLUT1 (Slc2a1 +/À ) in endothelium accelerated degenerative changes in the APPsw mouse model for AD . Degeneration of pericytes or vascular smooth muscle cells under hypoxic stress also leads to neurodegeneration and Ab clearance problems (Winkler et al., 2014) , suggesting that atherosclerosis and hypoperfusion of the brain might be an upstream cause in a subgroup of patients. In models of traumatic brain injury, the clearance flow is slowed down, which might contribute to accumulation of secreted Tau (Iliff et al., 2014) . Sleep increases, and aging and/or stiffening of the arterial wall slows down the glymphatic clearance flow (Tarasoff-Conway et al., 2015) . While it seems that vascular defects lead to amyloid accumulation, it may also be the case that Ab accumulation can lead to vascular defects as seen with some clinical APP mutations that manifest as CAA. Thus, Ab is both cause and consequence of vascular pathology, and this destructive cycle is an important part of the cellular action and reaction that underlies the cellular phase of AD.
Neurons and Neuronal Circuitry as Part of the Cellular Phase of AD
In the prevailing neuron-centric view, dysfunction of the brain is mediated by decrements in synaptic plasticity: e.g., long-term potentiation and depression, changes in homeostatic scaling, and disruption of neuronal connectivity. These alterations are currently often studied by recording synaptic function in neuronal cell and hippocampal slice models treated with Ab peptides, either synthetically generated, isolated from ''natural'' brain material, or expressed in transgenic mouse models. These models are too acute to mimic the progressive cellular disruption that occurs in AD brains over many years.
The complexity of how neurons are progressively affected by Ab stress has been addressed by a few groups. In a series of landmark publications, Palop and Mucke studied how Ab stress results in excitatory, (non-convulsive) seizure activity in neuronal networks (Palop and Mucke, 2010) . The study nicely illustrates how work in preclinical animal models can translate into novel insights relevant to human pathogenesis: epileptic seizures and neuronal hyperexcitability in AD patients became a recognized part of the condition (Bakker et al., 2012) . To explain the unexpected hyper-reactivity, they looked to cellular alterations and found loss of calbindin expression and ectopic expression of the inhibitory neuropeptide Y (NPY) in granule cells and mossy fibers, and GABAergic synaptic sprouting in the molecular layer emanating from NPY-and somatostatin positive interneurons. They also found a reduction in the voltage-gated sodium channel subunit Nav1.1 in parvalbumin cells, leading to defective inhibitory input that could be rectified by restoring channel expression (Verret et al., 2012) . Their data suggest that increased Ab stress in AD leads to a complex pattern of neuronal actions and reactions, causing aberrant excitatory network activity and compensatory inhibitory responses involving learning and memory circuitry (Palop and Mucke, 2010) . These fascinating studies are but a first step to address the complex cellular processes in AD. For example, recent work suggests that reactive astroglia in these mice secrete GABA, which paradoxically could contribute to seizure-like activity by suppressing inhibitory input on excitatory circuitry (Jo et al., 2014) .
Other mouse models also show that the neuronal reaction to Tau and Ab proteopathic stress is complex and not just simple cell death. Pyramidal cells in the frontal cortex show phases of hypo-and/or hyperexcitability in Tau and Ab mouse models (Menkes-Caspi et al., 2015) . Oscillatory network activity is altered in many AD models. Finally, the activity of hippocampal place cells that normally show a robust relation to animal location in the environment lose spatial selectivity in AD mice (Cheng and Ji, 2013) . Importantly, the recorded alterations are likely due to a mixture of direct and indirect effects of Ab on neurons and glial cells, synaptic dysfunctions that impact local network activity, and afferent activity in downstream targets and compensatory mechanisms. Disease progression likely entails an initial localized and acute direct or indirect effect of Ab species on cell and synaptic function, where distinct cell types may have a varying degree of sensitivity. The early local changes in network activity patterns would then progressively affect connected brain structures, followed by the spread of pathology.
An important caveat is that functional disturbances in mice are typically occurring in the absence of severe tangle formation and neuronal loss that characterizes AD dementia. Some investigators therefore severely doubt the validity of mouse experiments: a more moderate and constructive view is that the alterations in these mice recapitulate early alterations occurring in incipient AD brain (Zahs and Ashe, 2010) . In that sense, they are very relevant to the study of the early cellular phase of AD.
Morphological and biochemical studies of human brain material are limited to evolved stages of the disease. However, they too demonstrate the complex cellular phase in AD. Loss of innervation by the entorhinal cortex (EC) of the outer molecular layer of the dentate gyrus is associated with extensive sprouting of cholinergic innervation (Mufson et al., 2015) . Loss of input via the Schaffer collaterals is associated initially with increases in length and complexity of the basal dendritic trees of CA1 pyramidal neurons that become reduced only in the very advanced state of AD (Mufson et al., 2015) .
Astrocytes Are Central Players in the Cellular Phase of AD In contrast to neurons, the astroglia population is strikingly under-investigated in AD-related studies. Each astrocyte deploys many fine processes to contact up to 140,000 synapses in the CA1 region of rat hippocampus (Bushong et al., 2002) . With their end feet, they also contact blood vessels, forming the glia limitans of the BBB (Figure 2) . The astrocytes occupy anatomically and functionally discrete micro-domains (Bushong et al., 2002) , and arrays of astrocyte and neurons are organized around capillaries, providing the basis for higher-order neurovascular units (Allen, 2014) .
The metabolic roles of astroglia are well recognized (Figure 3 ). Importantly, astroglia and oligodendrocytes synthesize all brain cholesterol and secrete apolipoprotein E and apolipoprotein J that are loaded with cholesterol by ATP-binding cassette transporters-in particular, ABCA1. Synaptogenesis is promoted by glia-derived cholesterol, but there is also complex overlap between the lipid metabolism function of these various genes and the clearance of Ab over the BBB and blood-CSF barriers. Lipoprotein metabolism is strongly associated with risk for AD as repeatedly suggested in GWAS (Karch and Goate, 2015) .
Astroglia play an active role in synapse formation and synaptic strength regulation and in synchronizing and integrating the many synaptic processes under their control. Astroglia possess receptors and cognate signaling machinery for glutamate, GABA, adenosine, noradrenaline, acetylcholine, and endocannabinoids and respond to neurotransmitter release with calcium signaling (Figure 3) . They are thus well equipped to monitor neuronal activity. They also actively secrete gliotransmittors like ATP, glutamate, and D-serine that modulate activity of neuronal receptors (Allen, 2014) . In fact, astroglia participate in the ''tripartite synapse,'' providing a third component to the classical ''bipartite'' flow between pre-and postsynaptic neurons. Astrocytes thus both sense and modulate synaptic output and may exert an integrating role in the overall computing function of the brain (Allen, 2014; Gittis and Brasier, 2015) . Astrocytes are also involved in elimination of synapses via phagocytic receptors MEG10 and MERT (Chung et al., 2013) or via guiding microglial cells to synapses that are pruned involving the complement pathway. Recently, it was shown how this might operate in AD: NFkB is upregulated by Ab (Lian et al., 2015) and induces C3 release from the astrocytes. C3 binding to the G-proteinlinked receptor C3aR on neurons leads to alterations of dendritic morphology and network dysfunction. A C3aR antagonist improves performance of AD mice in the Morris water maze (Lian et al., 2015) .
Astrocytes are intimately involved in Ab catabolism, and Ab peptides affect their metabolic phenotypes. Astroglia are activated, express inflammatory markers early (Heneka et al., 2005) , and display abnormal synchronous Ca 2+ transients over long distances upon Ab exposure (Kuchibhotla et al., 2009) . Elevated Ca 2+ increases 1,4,5-triphosphate (IP 3 ) signaling and N-cadherin expression, which underlies astrogliosis. Likely several other signaling pathways are involved as well, and astroglial functionality should be considered when investigating mechanisms of Ab toxicity in brain. Local ablation of astrocytes in specific domains of the mouse brain causes neurodegeneration. This is partially because of increased excitotoxicity, as glutamate is no longer efficiently removed. However, the number of astrocytes is not markedly reduced in aging or AD brains (Pelvig et al., 2003) nor in various AD mice (Olabarria et al., 2010) . The contribution of astrocytes to AD neurodegeneration is thus clearly more complex than simple ''astrodegeneration'' and encompasses a whole spectrum of beneficial and harmful reactions (Figure 3) .
Reactive, Degenerating, and Atrophic Astrocytes in AD
The ''reactive'' astrogliosis in AD was noticed by Dr. Alzheimer himself. Reactive astrogliosis is a complex and dynamic response to brain damage (Burda and Sofroniew, 2014) characterized by astrocytic hypertrophy, proliferation, and augmented expression of intermediate filaments (glial fibrillar acidic protein [GFAP] , vimentin, and nestin). It is a physiological response and should, a priori, be considered a protective reaction; however, in AD, it could contribute directly to defective clearance because astrogliosis results in downregulation of Aquaporin 4 interfering with normal glymphatic flow. Astrogliosis is a relatively early event seen before the appearance of Ab deposits in an AD mouse model (Heneka et al., 2005) . PET studies measuring monoamine oxidase B (MaoB) activity in astrocytes confirm that astrogliosis is an early event in patients, with the largest signals seen in prodromal AD (Carter et al., 2012) . The relationship between amyloidosis, tau pathology, and astrogliosis remains enigmatic.
Experiments in various mouse models suggest that the astroglial reaction does not lead to astroglial scars as seen in injury models-i.e., the hypertrophy reflects morphological thickening of processes and soma, and the astroglia sustain support for the synapses in their unit. Indeed, attenuation of astrocyte activation (by deleting Gfap and vimentin genes) accelerates plaque pathogenesis in APP/PS1 mice (Kraft et al., 2013) . Moreover, a marked increase in dystrophic neurites was seen, indicating the protective nature of the astrogliosis reaction in the mice. Another group, however, found the opposite effect in similar models (Kamphuis et al., 2015) , and whether astrogliosis is beneficial or harmful remains an open question. Indeed, it might be that the answer depends upon the stage of the cellular phase of AD and the brain region affected (Olabarria et al., 2010) . The paradoxes in the different studies will probably only be resolved when the progressive and divergent cellular responses in AD are systematically and comprehensively delineated.
Atrophy of astroglia, characterized by reduced branching, is also seen at 1 month in the entorhinal cortex and at 3 months in the prefrontal cortex of triple transgenic AD mice (KulijewiczNawrot et al., 2012) . This could lead to defective metabolic support and shrinking of their territorial domain, leading to synaptic dysfunction. Atrophy of astroglia was independently observed in another AD mouse (Beauquis et al., 2014) . Studies linking morphological changes to functional alterations are limited. Jo et al. (2014) provide insight in how MaoB (which is upregulated in AD patients [Carter et al., 2012] ) increases GABA in reactive, GFAP-positive astroglia in the dentate gyrus of APP/PS1 mice. Release of GABA causes a tonic inhibition of perforant path/ dentate granule cell synapses. Two other studies link the G s -protein-coupled adenosine receptor A 2A expressed on astroglia to memory defects in Tau-and APP-mice (Orr et al., 2015) . The A 2A -receptor is increased in AD brain, and these new studies demonstrate that specific antagonists can restore memory (and possibly decrease Tau-pathology) in models for AD.
Microglia and Inflammation: Beneficial or AD Promoting Effects?
Microglia, the phagocytic cells of the CNS, comprise between 5% and 12% of the cell population in the adult mouse brain (Lawson et al., 1990) and are a recognized part of the cellular phase of AD. Seminal observations by McGeer et al. (1988) demonstrated their intimate association with senile plaques. Since then, their role and, more generally, the role of inflammatory processes (which also involves astrocytes and monocytes) in the pathogenesis of AD have been intensively investigated [Heneka et al., 2015] ). The role of microglia in AD is likely broader than inflammation alone. These cells constitute a dynamic population that samples the local brain environment continuously with highly ramified processes and interacts intimately with neurons (Li et al., 2012) . Microglia phagocytose supernumerary neurons during normal development and can directly induce neuronal apoptosis (Salter and Beggs, 2014) . More subtle actions, such as synaptic pruning, are also part of their repertoire.
Highly replicable data show complement activation, increases in inflammatory cytokines in the CSF, increased levels of reactive oxygen species, and so on, in AD. Epidemiological studies suggest, in addition, a potential inverse correlation between the use of non-steroidal anti-inflammatory drugs and AD prevalence (Heneka et al., 2015) , although interventional studies with antiinflammatory drugs have all been negative to date. Recent genetic data unequivocally place inflammatory processes as being important in AD. A series of GWASs of increasing size revealed 22 susceptibility loci (Lambert et al., 2013) of which a large group clearly could be ascribed to pathways within innate immune system regulation ( Figure 2 ): complement receptor 1 (CR1), clusterin, CD33, the MS4A6-MS4A4 cluster, ABCA7, CD2AP, EPHA1, HLA-DRB5-DRB1, INPP5D, and MEF2C (Karch and Goate, 2015) . However, for most of these associations, it is not possible to ascribe changes in biological function to the identified gene or, indeed, whether the polymorphisms are in disequilibrium with other genes that harbor the relevant biological function.
A critically important finding from two groups revealed that rare mutations to the triggering receptor expressed on myeloid cells 2 (TREM2) gene significantly increased the risk of late onset AD by about 3-to 5-fold (Guerreiro et al., 2013; Jonsson et al., 2013) -an increase in risk on a par with that of APOE4. TREM2 mutations can also increase the risk of other neurodegenerative diseases, suggesting some commonality in the underlying pathological processes. At the same time, a very large study of late onset AD patients versus controls using whole-genome geneexpression profiling (Zhang et al., 2013) demonstrated that a module grouping innate immunity/microglia related genes correlated best with clinical disease. TYROBP ranked highest as the module's potential regulator. TYROBP, otherwise known as DAP12, encodes the signaling partner for TREM2. Thus, using radically different approaches, microglial function and TREM2 signaling are found to play a major role in SAD.
TREM2 is a type I transmembrane protein that is expressed on the surface of osteoclasts, immature dendritic cells, macrophages, and, in the CNS, on microglia. TREM2 ranks as one of highest expressed receptors on microglia, where its expression is >300-fold that of astrocytes (Hickman and El Khoury, 2014) . Homozygous, loss-of-function mutations in TREM2 and its adaptor molecule DAP12 (TYROPB) cause Nasu Hakola disease that is characterized by dementia, white matter loss, and cystic bone lesions. TREM2 binds to a range of poorly defined ligands such as phospholipids, bacterial products, and cell debris, and receptor binding mediates microglial phagocytosis and promotes an anti-inflammatory cytokine profile. The greatest risk for AD is associated with the R47H variant, which causes loss of function by preventing normal folding of the protein (Kleinberger et al., 2014) . An obvious hypothesis is that TREM2 is triggering the phagocytosis of Ab plaques (Kleinberger et al., 2014) . Another microglia risk gene, CD33, apparently also inhibits uptake of Ab but via a gain-of-function mechanism, as it is upregulated in SAD (Griciuc et al., 2013) .
To assess the effects of Trem2 in vivo, APP/PS1 transgenic mice were crossed with Trem2 À/À mice (Ulrich et al., 2014; Wang et al., 2015) . The results are divergent. In one study (Ulrich et al., 2014) , no effects on Ab plaque load, cytokine levels, or microglial activation were recorded. The only reported difference was a reduction in the numbers of microglia that clustered around plaques. In the second study, which used a different model-i.e., the 5XFAD mice-Trem2 knockout resulted in a gene dosage increase in brain Ab plaques, accompanied by significantly reduced expression of microglial markers of activation and inflammatory cytokines. Thus, this work suggests that Trem2 plays an important role in the microglial inflammatory response: in the absence of Trem2, this response is diminished. Apart from their phagocytic capacities, microglia express a range of cell-surface receptors that activate innate immune responses. This allows microglia to mount protective responses to damage-associated molecular patterns, such as Ab aggregates. In particular, a number of studies have implicated the CD36 scavenger receptor and the Toll-like Receptor 4 (TLR-4) in mediating inflammatory cytokine release in response to aggregated Ab. Data on the role of microglia and inflammatory mediators on the deposition and clearance of Ab plaques in APP transgenic mice are again mixed, with some researchers finding amelioration and others exacerbation of plaque deposition. Recently, two groups looked at the effects of Interleukin 10 (IL10) on amyloid pathology in APP transgenic mice, with very concordant results. Interleukin 10 is a cytokine that inhibits inflammatory cytokine signaling. Increasing its expression in two APP transgenic mouse models using adeno-associated virus mediated brain expression (Chakrabarty et al., 2015) caused an increase of deposited Ab 42 and plaque burden. The authors postulate that IL10-mediated increases in astrocyte ApoE production led, in turn, to an elevation of ApoE binding to Ab plaque that reduced microglial phagocytosis-although this appears to be at variance with data showing binding of ApoE to Trem2 (Atagi et al., 2015) . In the second study (Guillot-Sestier et al., 2015) , the investigators crossed APP/PS1 transgenic mice with IL10 À/À knockout mice. In a similar fashion, but with an opposite polarity, the IL10 deficiency reduced insoluble, deposited Ab. Another study investigated the effects of removing microglia from the brain altogether (Grathwohl et al., 2010) . Using different gangciclovir dosing regimens, it was possible to remove nearly 100% of the microglia, albeit for a relatively short duration of up to 4 weeks. In no case was the deposition or clearance of amyloid plaques altered.
Collectively, these examples illustrate the conundrum of inflammatory processes: in some situations they can be beneficial, in others, damaging. A more integrated approach seems necessary to investigate the progressive inflammatory and other responses, and a more comprehensive analysis of the role of the different cells (microglia, but also astroglia and infiltrating monocytes) over the different stages of the cellular phase of AD is needed. Indeed, what is beneficial in the beginning could become destructive later. Finally, inflammation must be placed into the wider context of aging. The AD brain carries the hallmarks of an inflammatory process, but it is also apparent that age itself predisposes to inflammation-a concept that has been coined as ''inflammaging.'' In a fascinating study, an analysis of gene expression profiles of immune-and inflammationrelated genes was conducted across a range of ages of normal and AD brains (Cribbs et al., 2012) . This study demonstrated that the increase in expression of immune/inflammation-related genes with age far exceeded that seen in AD versus normal brains. The conclusion from this work is that, with age, the brain becomes predisposed to inflammatory processes, which might explain why age is the greatest risk factor for AD.
Oligodendrocytes: A Silent Majority
The roles of oligodendrocytes in AD are even less studied than those of astrocytes, although evidence supports their role in the cellular phase of the disease (Ettle et al., 2015) . Oligodendrocytes constitute $75% of the neuroglia cells in the neocortex and are therefore the largest group of non-neuronal cells in the brain (Pelvig et al., 2008) . They produce myelin and facilitate neuronal transmission via saltatory action potential conductance over the nodes of Ranvier. They also provide buffer capacity for potassium, metabolic, trophic, and mechanic support to axons. They are considered highly vulnerable cells and show a dramatic (À27%) decrease in number in the aging brain (Pelvig et al., 2008) . This cellular loss is reflected in age-associated myelin breakdown as seen in MRI scans of patients from age 50 on (Bartzokis, 2011) . Oligodendrocyte progenitor cells, characterized by the expression of the proteoglycan nerve-glial antigen NG2, provide up to 5% of the cells in the mature brain. They are the main proliferating cells and can differentiate into oligodendrocytes, astrocytes, and possibly neurons, although this pluripotency remains an issue of debate (Crawford et al., 2014) .
Braak suggested a link between vulnerability of neurons and their myelination stage because the spreading of neurofibrillary tangles recapitulates the pattern of myelination in reverse order (Braak and Braak, 1996) . Later differentiating oligodendrocytes en-sheath more axons with small axon diameters as seen in late myelinating frontal and temporal lobes (Bartzokis, 2011) , and it might be that these make these areas more vulnerable to all kinds of stresses. Bartzokis goes even as far as to propose that the recently evolved extensive myelination of the human brain explains increased vulnerability to neurodegenerative and neuropsychiatric disorders (Bartzokis, 2011) . Age-related myelin breakdown as assessed by MRI might indeed result in a progressive disconnection of neural networks and presage AD (Bartzokis, 2011) . One of the more compelling arguments to increase focus on oligodendrocytes and possible demyelination is the strongly accentuated age-related breakdown of myelin in AD and in APOE4 patients (Bartzokis, 2011; Scheltens et al., 1992) . At the cellular level, Ab deposition is linked to focal demyelination. In APP/PS1 mice, an early demyelination phenotype is seen that is apparently ''repaired'' by proliferation of oligodendrocyte progenitor cells at 6-8 months (Behrendt et al., 2013) . Such proliferation is not observed in AD brain, suggesting that this putative ''protective'' reaction does not occur in patients (Behrendt et al., 2013) . Oligodendrocyte progenitor cells appear to phagocytose Ab while Ab triggers deficits in oligodendrocytes in different mice models (Desai et al., 2010) . Other molecular links between AD and oligodendrocytes include their central role in lipid metabolism, discussed above, and the role of BACE1 in neuregulin processing.
Systems Biology Approaches to Study the Cellular Responses in AD
The complexity emerging from the current analysis of the literature stresses the importance of generating a new theoretical framework that encompasses the many parallel processes that go astray in the brains of AD patients. Typically, systems biology addresses such questions, but the ''big data'' approaches, excepting the genetic studies, have not yet yielded spectacular new insights into AD pathogenesis. Available studies characterize global alterations of mRNA (Bennett et al., 2014; Bossers et al., 2010; Matarin et al., 2015; Miller et al., 2010; Zhang et al., 2013) or miRNA expression (Lau et al., 2013) , thus aggregating all changes in neurons, interneurons, astroglia, oligodendrocytes, and microglia of the analyzed brain block with a consequent loss in resolution. Typically, small expression changes of thousands of genes are recorded. Systems biology uses sophisticated statistical methods to correct for the multiple testing of hypotheses and involves a series of assumptions to increase the power of analysis-for instance, that complex diseases disturb complex biological pathways and that the genes in these pathways are co-regulated (Santiago and Potashkin, 2014) . Other assumptions are that key regulators of biological networks can be discovered by identifying regulatory patterns of co-expressed genes or by finding gene expression correlation patterns between different samples (differential co-expression network analysis or DCA) and that proteins in pathways interact directly in a protein complex or in a small protein interaction network (protein-protein interaction or PPI analysis). In AD, real experimental validation of the conclusions of such analyses is mostly lacking. A notable exception is the study on transcription/neuron-restrictive silencer factor (REST/NRF) (Lu et al., 2014) . Data mining of transcription profiles from prefrontal cortex of aging humans predicted that REST/NRF was activated in aging brains but less so in AD (Lu et al., 2014 ). An impressive series of experiments in human brain and in mouse and C. elegans genetic models demonstrated that REST expression is neuroprotective, represses genes that promote cell death, increases oxidative stress resistance by de-repressing FOXO1a and SOD1 expression, and maintains neuronal viability in the aging cortex (Lu et al., 2014) , providing crucial insight in protective mechanisms that, when malfunctioning, contribute to the risk for neurodegenerative disease.
As stated, other available systems biology studies in the field are more descriptive. Altered regulation of transcription and cell proliferation, changes in energy pathways or mitochondria, upregulation of complement activation, inflammation, lipid metabolism, or downregulation of synaptic transmission are expected (Matarin et al., 2015; Zhang et al., 2013) . Further analyses try to identify molecular players that act as drivers or are critical in the overall processes identified. One study found downregulation of tumor suppressors and focused also on changes in oligodendrocyte growth factors. Another study found significant changes in a human-specific module (group of highly co-expressed genes) that closely correlated with AD progression. The authors speculate that the hubs in this network are important parts of the AD process (Miller et al., 2010) . However, none of those hubs has been further validated, and one (FLJ12151) has even been withdrawn as a gene by NCBI. Overall, this study found major links with oligodendrocytes, astroglia, and microglia, re-enforcing the major theme of the current review. As previously mentioned, TYROBP, was identified as a regulator of an immune-and microglia-specific module in a study in 549 brains from late-onset patients and non-demented subjects (Zhang et al., 2013) . Although only upregulated by 18%, the authors boldly conclude that TYROBP may be a therapeutic target in prevention of neuronal damage in LOAD, supported by the genetic data found in other studies (vide supra).
There are many reasons why systems biology approaches are currently not yielding novel insights in our field. Further massive data gathering is of questionable use unless systematic, quality controlled, in-depth phenotypic information is associated with the samples (Bennett et al., 2014) . However, in addition, massively collecting ''omic'' data from blocks of brain material probably lacks the granularity required to dissect key aspects of the disease process. The brain is the most complex structure of the human body with an incredible variety of cell types. The lack of cellular resolution makes it very likely that dramatic changes in gene expression in particular cell types or groups of cells will be diluted or lost by the absence of effects in other cell groups. The interpretation of data from brain blocks might be very misleading with regard to the cell type affected in the disorder.
Single-Cell Populations and Resolution over Different Stages of Disease
A recent systems biology study in AD mice strikingly illustrated the above point by looking separately at astrocytes and microglia (Orre et al., 2014) . The immune pathways were much more affected in astrocytes than in microglia, and interestingly, while the recorded alterations in astrocytes were remarkably similar to the alterations recorded in human AD brain, the microglial changes showed much less similarity (Orre et al., 2014) . Individual changes in expression of genes were much more pronounced than in the ''whole brain block'' studies. Tyrobp expression increased almost 10-fold (compared to the overall 18% increase reported in human AD [Zhang et al., 2013] ), and Trem2 increased more than 9-fold in the astrocytes while both were conspicuously absent in the list of microglia associated gene changes (Orre et al., 2014) . While Trem2 expression is much lower in astrocytes than in microglia (Hickman and El Khoury, 2014) , these dramatic and consistent changes in gene expression provide high confidence that they are real and will translate to biologically significant effects. The study clearly illustrates how important it is to provide cellular resolution when performing whole-genome analyses of the brain.
Temporal resolution is also important. In particular, studies on human tissue tend to pool the data without taking into account disease duration or evolution. A study following global gene (Bossers et al., 2010) and miRNA (Lau et al., 2013) expression in the prefrontal cortex over different Braak stages of AD demonstrated major changes between Braak stage II and III, which is just before or at the onset of plaque and tangle pathology. Unexpectedly, and in contrast with other genome-wide studies, increases in synaptic plasticity genes came up in this early phase, while downregulation was only seen in the late stage of AD (Bossers et al., 2010) . The miRNA study demonstrates complex patterns of change in 41 miRNA with a 2-to 3-fold decrease in miRNA132 expression standing out in this analysis (Lau et al., 2013) . Unfortunately, the dataset encompasses only 49 brains at the moment, and therefore, statistical power is limited. Expanding this dataset and providing in addition cellular resolution would be extremely helpful for the field.
Real temporal resolution can only come from animal studies where brain samples can be taken from cohorts of mice at different stages of the disease. One such study compared gene expression alterations over time in Ab-and Tau-models of the disease (Matarin et al., 2015) . Mainly immune-related changes were recorded, with an immune module strongly associated to amyloid pathology, and genes related to synaptic function most altered in the Tau model. Cellular resolution, however, was lacking.
The Future: Single-Cell Biology and Cellular Network Analysis in the Study of AD Breakthroughs in the study of the biochemical phase of AD are still needed, and an excellent example was the recent elucidation of the atomic structure of g-secretases, opening a complete new perspective on drug discovery for this important AD target (Bai et al., 2015; De Strooper, 2014) . However, it is unlikely that molecular genetics or molecular cell biology will continue to propel our understanding of the disorder in as productive a way as it has over the last 20 years. The major challenge for AD research is now to understand the complex cellular reaction underlying the long prodromal phase of AD. Cellular and temporal resolution will be crucial to map systematically the progressive cellular alterations and to generate a comprehensive cellular theory of the disorder. AD is indeed not a biochemical or molecular problem but a physiological one of disrupted cellular connectivity. The disease can therefore only be fully understood in the context of the complex cellular interactions that maintain homeostasis in the brain-i.e., at the level of the neurovascular and glioneuronal units discussed above.
Spectacular progress in ''single-cell biology'' (Sandberg, 2014) over the last 3 years makes it possible to map alterations in gene expression in many different cell types in parallel. The strong advantages of a single-cell approach are (1) agnosticism with respect to cell type (allowing also the discovery of new cell types) and (2) that information on the variation in responses over a subpopulation of cells can be evaluated-e.g., do all astroglia, interneurons and so on, respond in the same way and at the same time to Ab stress? Two recent publications provide proof of concept that genomic expression data from hundreds of individual cells from mouse hippocampus (Zeisel et al., 2015) and human cortex (Darmanis et al., 2015) can be resolved successfully. In addition, spatial transcriptomics is rapidly evolving, and spatial resolution of genome-wide gene expression in cells is becoming possible. A limitation of current approaches is that changes are recorded only at the transcriptional level. However, cells react by changes in gene expression, and pathway analysis will help to indicate processes affected in the different cells.
A framework could be generated by measuring all changes in the different cell types of the brain over the different Braak stages in a few relevant brain areas, which would constitute a valuable resource for the field and propel AD research into the complex biology of the 21 st century. Further experimentation and validation of hypotheses at the protein and in vivo level will still use classical reductionist approaches and yield individual insights, but being able to fit such pieces into the time, cell, and network dependent atlas that describes the evolution of Alzheimer's disease will be transformative for the field. Novel ideas will emanate from such an insight and an integrated conceptual framework will provide a scientifically coherent basis for targeted therapeutics that address different elements of the disease in a stagedependent manner.
